Safety and efficacy of tissue-type plasminogen activator produced by recombinant DNA technology
- 1 November 1987
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 10 (5) , 40B-44B
- https://doi.org/10.1016/s0735-1097(87)80427-8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.Circulation, 1986
- High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trialJournal of the American College of Cardiology, 1985
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Coronary Thrombolysis with Tissue-Type Plasminogen Activator in Patients with Evolving Myocardial InfarctionNew England Journal of Medicine, 1984
- Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1984
- Clot-Selective Coronary Thrombolysis with Tissue-Type Plasminogen ActivatorScience, 1983